GlassScriptPhysician profile
Jason Alexander Walker
NPI 1760437859
$1,059.81
in general payments reported to CMS, 2019-2025
27 companies · $38.09 in 2025
The $38.09 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.30 · 2020: $42.21 · 2021: $136 · 2022: $251 · 2023: $215 · 2024: $295 · 2025: $38.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Masimo Corporation | $104.85 | 2020-2021 | |
| Abbvie INC. | $102.67 | 2019-2023 | Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $102.24 | 2024 | Fluent Fluid Management System, Myosure Tissue Removal Device, Novasure |
| Intuitive Surgical, INC. | $90.72 | 2022 | |
| Exeltis, USA INC. | $78.52 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $70.37 | 2023-2024 | |
| Astellas Pharma US INC | $60.42 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $41.51 | 2019-2024 | |
| Coopersurgical, INC. | $39.37 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Ethicon US, LLC | $33.60 | 2022-2024 | Enseal X1, Enseal |
| Pfizer INC. | $31.47 | 2021-2023 | |
| Shield Therapeutics INC | $31.28 | 2023-2024 | Accrufer |
| Stryker Corporation | $28.87 | 2021 | |
| Avion Pharmaceuticals | $28.08 | 2019-2022 | |
| Aspira Women'S Health INC | $21.90 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $21.73 | 2023 | Myfembree |
| Lsi Solutions INC | $20.73 | 2025 | Fornisee, Running Device, Ti-Knot |
| Biogen, INC. | $20.08 | 2024 | |
| Sage Therapeutics, LLC | $18.77 | 2022 | |
| Evofem Biosciences, INC. | $18.51 | 2023 | Phexxi |
| Otsuka America Pharmaceutical, INC. | $17.70 | 2022 | |
| Therapeuticsmd, INC. | $17.45 | 2022 | |
| Merck Sharp & Dohme LLC | $17.17 | 2023 | Gardasil 9 |
| Novo Nordisk INC | $16.19 | 2024 | Wegovy |
| Medline Industries LP | $13.52 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.09 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.